Mind Medicine (MNMD) is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines to address addiction and mental illness. Its executive team brings extensive biopharmaceutical experience to its groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.
The company has several projects in various stages of development ranging from planning to ongoing trials. These include LSD, DMT and a ibogaine derivative called 18-MC.
Anxiety disorders are among the most prevalent mental illnesses worldwide. They are also a leading cause of disability and suffering.
Psychedelics have shown great promise in the treatment of anxiety and other psychiatric disorders, but they have only been studied in eight clinical trials to date. This new study is a huge step in changing that narrative.
MindMed has partnered with the University of Basel in Switzerland to conduct investigator-initiated studies using a drug called MM-120. This is a proprietary version of LSD designed for medical applications.
MM-120 is currently being tested in an ongoing Phase 2 trial, which involves 200 patients and will assess how much it reduces anxiety symptoms over 12 weeks. Researchers say this trial will help them determine how to dose a Phase 3 trial (which generally focuses on larger numbers of patients and looks at how a medicine works compared to existing treatments).
Depression is a mental illness that affects the brain and can have a negative impact on a person’s life. It affects the mood, energy levels, sleep and appetite. People with depression may also have problems concentrating or losing interest in previously enjoyable activities.
In many cases, people with depression can get relief through psychotherapy or antidepressant medication. Depending on the severity of the depression, treatment may take a few weeks or more.
Psychotherapy can be used alone for mild depression or in combination with an antidepressant medication to treat more severe cases. It can be very effective in helping people to recognize distorted thinking and change it with more productive thought patterns.
Psychedelic-assisted therapy has been shown to reduce symptoms of depression. It has also been shown to increase feelings of motivation and arousal, which can help people who suffer from anxiety disorders or PTSD.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a condition that affects people in many different ways. It can cause problems at school and home, in social situations and with work.
Children and adults with ADHD have difficulty paying attention, controlling impulsive behaviors or being overly active. The symptoms of ADHD may worsen in adolescence and adulthood, but they can be effectively treated and controlled.
The primary symptom is problems with attention. This includes trouble focusing during lectures, reading or conversations and having difficulty following directions and finishing tasks.
Those with ADHD may also lose track of time or misplace items, have difficulty remembering things and are easily distracted. Inattention can lead to school difficulties, job failure or unemployment and social problems.
Parents and caregivers can help children with ADHD manage their symptoms by recognizing that the behavior is not their fault. They may need help learning how to set clear rules for their children and ensuring that they are working towards the same goals.
Pain is a significant source of suffering in many people’s lives. It is one of the most common medical conditions that people deal with and is a major factor in substance abuse, suicide and chronic health problems.
Although psychedelics have been shown to be effective in treating anxiety and depression, they have not yet proven to offer patients relief from chronic pain. MindMed, a company that recently launched a study series called Project Angie, is exploring this potential with LSD, which has been used in psychedelics for decades and has been shown to have analgesic effects.
According to MindMed’s Chief Development Officer Rob Barrow, the company is currently preparing an IND briefing package for a Phase 2a Proof of Concept study evaluating LSD for severe pain. It is also evaluating a second clinical indication for chronic pain syndrome.